Nexelis Acquires GSK Vaccines Clinical Bioanalytical Laboratory (Marburg)

Nexelis to Acquire ImmunXperts

April 4, 2020

Healthcare Services

Nexelis, a portfolio company of Ampersand Capital Partners, has signed a definitive agreement to acquire ImmunXperts, a specialty immunogenicity and immuno‑oncology testing laboratory based in Gosselies, Belgium. The add-on deal will expand Nexelis' assay development and immunology testing capabilities and is expected to close by the end of March 2020.

Q² Solutions (IQVIA) Acquires Nexelis from Ampersand Capital Partners

January 10, 2022

Healthcare Services

Ampersand Capital Partners sold its portfolio company Nexelis to Q² Solutions, a wholly owned subsidiary of IQVIA, Inc. Nexelis, a Laval, Quebec–based provider of assay development and advanced clinical-trial laboratory testing with five operating sites in North America and Europe, will be integrated into IQVIA's global laboratory services to expand capabilities and capacity for vaccine, immunology and other drug-development testing.

BioAgilytix Acquires Cambridge Biomedical

November 4, 2019

Healthcare Services

BioAgilytix, a GHO Capital portfolio company, has acquired Cambridge Biomedical, a Cambridge, Massachusetts–based clinical research organisation specializing in large-molecule bioanalysis. The deal expands BioAgilytix's laboratory capacity and capabilities (including CLIA/CAP/GLP capabilities and PCR/molecular suites), broadens its geographic footprint into the Boston/Cambridge biotech cluster, and strengthens its cell- and gene-therapy bioanalytical offerings.

Nexelis Acquires AIT Bioscience

July 22, 2020

Healthcare Services

Nexelis, a portfolio company of Ampersand Capital Partners, has acquired AIT Bioscience, an Indianapolis-based integrated bioanalytical CRO with LC‑MS and immunoassay testing capabilities. The add-on expands Nexelis' bioanalytical services (including large-molecule mass spectrometry) and establishes operations in Indianapolis to support future growth and faster turnaround times.

GSK Acquires BELLUS Health

April 18, 2023

Biotechnology

GSK plc agreed to acquire Canada-based late-stage biopharmaceutical company BELLUS Health for US$14.75 per share, representing an approximate total equity value of US$2.0 billion. The acquisition gives GSK access to camlipixant, a Phase III P2X3 antagonist for refractory chronic cough, and is expected to close in Q3 2023 subject to approvals.

Biosynth Acquires celares to Expand Bioconjugation and Polymer Drug Delivery Capabilities

July 11, 2023

Biotechnology

Biosynth, a Switzerland-based supplier of critical raw materials and manufacturing services, acquired Berlin-based celares, a developer and manufacturer of bioconjugates, activated PEGs and polymer-based drug delivery excipients. The acquisition strengthens Biosynth's capabilities in conjugate vaccines and bioconjugate drugs and adds GMP bioconjugation and PEGylation manufacturing in Berlin to its service offering.